ReviewJournal of clinical medicine2022
The Role of Sclerostin in Bone Diseases.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.Current medicinal chemistry · 2026Pooled it
- Serum sclerostin in vascular calcification in CKD: a meta-analysis.Renal failure · 2023Pooled it
- A bioprocessing approach for osteogenic differentiation: combining electrical stimulation with the F1 protein fraction from natural latex of Hevea brasiliensis.Bioprocess and biosystems engineering · 2026Article
- Bone‑origin repair in diabetic foot ulcers: Mechanisms of callus formation and endocrine effects in healing (Review).International journal of molecular medicine · 2026Review
- The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention.Science China. Life sciences · 2026Review
- Analysis of serum biomarker profiles in DDH Hip osteoarthritis versus primary hip osteoarthritis: a prospective observational study in a recent arthroplasty cohort.Journal of orthopaedic surgery and research · 2026Observational
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- Peptide Receptor-Functionalized AuNP-Embedded Zwitterionic Biopolymeric Nanohydrogel for Electrochemical Sclerostin Sensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Sclerostin silencing in human umbilical cord mesenchymal stem cells enhances bone regenerationWorld journal of stem cells · 2026Article
- Branched‑chain amino acid metabolism and bone metabolism: Implications for osteoporosis pathogenesis and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Cold exposure and human metabolism: A heterogeneous response across tissues and organs.Temperature (Austin, Tex.) · 2026Review
- Research Progress of Injectable Hydrogels Targeting Specific Pathogenesis for Osteonecrosis of the Femoral Head.International journal of nanomedicine · 2026Review
- The role of post-translational modifications in osteonecrosis of the femoral head.Frontiers in cell and developmental biology · 2026Review
- Role of Branched-Chain Amino Acids in Mitigating Osteosarcopenia: An Experimental Study Using Ovariectomised Mice Models.Journal of cachexia, sarcopenia and muscle · 2025Article
- Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies.Inflammopharmacology · 2025Review
- MLM3 and MLM5 head and neck cancer models promote age-dependent musculoskeletal deterioration in mice.Scientific reports · 2025Article
- Bone Mineral Density and Serum Levels of Bone Remodeling Markers in Ankylosing Spondylitis Treated with Anti TNF-α Agents.Medical sciences (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.